8-Nitrotryptanthrin inhibits colorectal cancer progression via TGF-β/SMAD and PI3K/AKT/mTOR pathways
CRC is a global health challenge with limited treatments for advanced stages. This study provides the first evidence of 8-Nitrotryp's antitumor efficacy in CRC, demonstrating its dual inhibitory activity on the TGF-β/SMAD and PI3K/AKT/mTOR pathways. Compared to Tryp, 8-Nitrotryp exhibits markedly enhanced potency, with lower IC<sub>50</sub> values due to the introduction of a nitro group. Furthermore, the suppression of EMT is mechanistically linked to TGF-β/SMAD pathway inhibition. These findings suggest 8-Nitrotryp's potential as a novel therapeutic for CRC.
Authors
- Enguo Fan (ORCID: https://orcid.org/0000-0003-0921-2432)
- Kai-Ping Cong
- Mingquan Guo (ORCID: https://orcid.org/0000-0002-6627-5627)
- Dandan Zhao (ORCID: https://orcid.org/0000-0001-9375-2997)
- Zhengguo Zhang (ORCID: https://orcid.org/0000-0002-3727-6778)
- Chengyu Sun (ORCID: https://orcid.org/0000-0002-2372-7558)
Institutions
- Jiangsu Normal University (CN)
- Xuzhou Medical College (CN)
- Chinese Academy of Sciences (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Ningbo Institute of Industrial Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.3389/fphar.2025.1576673
- Citations
- 3
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 4.41